Answers are grounded in this paper and cite their sources.
OBJECTIVE: Although chemotherapy is widely used in the treatment of cancer, it suffers due to the nonspecific biodistribution and side effects of chemotherapy agents. In this study, a nano formulation that can both prevent the formation of drug resistance and increase the effectiveness of treatment was developed. MATERIAL AND METHODS: Docetaxel (DTX) and Combretastatin A4 (CA4) loaded PEG-PLGA (Poly(ethylene glycol)-block-Poly(lactide-co-glycolide) polymeric nanoparticles were fabricated with mono and binary drug loading. The size and morphology of the nanoparticles were characterized using Transmission Electron Microscopy (TEM). The UV-Vis spectrometer determined critical Micelle Concentration (CMC) values, drug encapsulation efficiency, and drug release profiles of the mono and binary drug-loaded nanoparticles. In vitro efficiency of the DTX and CA4 loaded PEG-PLGA nanoparticles was tested using a human breast cancer cell line (MCF-7) compared to free drug formulations. RESULTS: PEG-PLGA nanoparticles had a CMC value of 0.0126 mM. The size of the particles was measured at around 5-10 nm. They released almost all loaded content in 4 days at pH 5.5, whereas this value remained 60% at pH 7.4. DTX and CA4 loaded nanoparticles showed a lower EC50 value than the dual free drug formulation. CONCLUSIONS: The designed nano dual drug formulation can be an alternative chemotherapy solution for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Kağa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: